PTC Therapeutics sees FY22 revenue $710M, consensus $729.35M

Preliminary Unaudited 2022 Financial Results: Total unaudited net revenue for full year 2022 was approximately $710 million. Total unaudited net product revenue for full year 2022 was approximately $535 million. DMD franchise unaudited revenue for full year 2022 was approximately $507 million, including net product revenue for Translarna of approximately $289 million and for Emflaza of approximately $218 million. PTC expects to report approximately $175 million in 2022 collaboration and royalty revenue associated with Evrysdi. PTC is currently in the process of finalizing its financial results for the 2022 fiscal year. The above information is based on preliminary unaudited information and management estimates for the full year 2022, subject to the completion of PTC’s financial closing procedures. Evrysdi royalty revenue estimates are based on sell side analyst consensus estimates.